Sanofi stock after-hours at EUR 72.54: minus 0.45 percent versus prior close
Published on 10/01/2026 at 22:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Sanofi stock traded at EUR 72.54 in after-hours trading at 10:39 p.m. CEST on October 1, 2026, down EUR 0.33, or 0.45 percent, versus the EUR 72.87 prior close at Lang & Schwarz.
Sanofi stock after-hours
The current price is below the previous Lang & Schwarz close of EUR 72.87. The further course of after-hours trading at Lang & Schwarz until 11:00 p.m. CEST is shown by the continuously updated real-time quote of Sanofi stock.
Sanofi expands Regeneron alliance
Sanofi and Regeneron announced on October 1, 2026, that they had expanded their longstanding antibody collaboration. Under the agreement, the companies will co-develop and co-commercialize four new long-acting antibodies targeting interleukin-13, an IL-4xIL-13 bispecific, interleukin-4 and interleukin-4 receptor alpha, according to Sanofi.
Upfront payment and development plans
Regeneron will receive a USD 1 billion upfront payment from Sanofi and could receive up to an additional USD 7 billion in development, regulatory and commercial milestones. The companies will share development and commercialization costs and split future profits from the new programs 50:50 globally. Regeneron will lead research and development, while Sanofi will lead global commercial efforts, the company said in its release.
The antibody REGN20423 is currently in a phase 1 clinical study for atopic dermatitis, while the other three programs are expected to enter clinical studies in 2027. The existing profit-sharing agreement for Dupixent will not change, according to Sanofi.
